Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
Rhea-AI Summary
Soligenix (Nasdaq: SNGX) reported Q1 2026 results and program updates on May 8, 2026. The pivotal Phase 3 FLASH2 trial of HyBryte was halted for futility after an interim analysis; the company will analyze subgroup data and may discuss next steps with EMA and FDA.
Net loss was $2.8M and cash was approximately $6.0M at March 31, 2026, with runway into the second quarter of 2027; management is evaluating strategic options including M&A and advancing SGX945.
AI-generated analysis. Not financial advice.
Positive
- Cash balance of approximately $6.0M at March 31, 2026
- SGX945 received EMA orphan drug and UK MHRA PIM designations
- Comparability study of HyBryte vs Valchlor published in Oncology and Therapy
- Phase 2 data showed promising biological efficacy for SGX945 in Behçet's Disease
Negative
- Pivotal Phase 3 FLASH2 trial halted for futility after interim analysis
- No revenue reported for the quarter ended March 31, 2026
- Net loss of $2.8M for Q1 2026, with cash runway only into Q2 2027
- HyBryte did not reproduce the prior 6-week efficacy signal in FLASH2 (18 weeks)
News Market Reaction – SNGX
On the day this news was published, SNGX declined 4.93%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $165K from the company's valuation, bringing the market cap to $3.18M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNGX was down 6.89% while momentum peers like XTLB and IMNN appeared in scanners with gains above 5%, indicating today’s move was more stock‑specific than sector‑wide.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Year-end 2025 results | Neutral | +6.3% | Reported 2025 net loss, cash of $7.9M, and outlined key 2026 milestones. |
| Nov 07 | Q3 2025 results | Neutral | +7.0% | Q3 2025 net loss, no revenue, R&D spend and HyBryte Phase 3 safety update. |
| Aug 14 | Q2 2025 results | Neutral | +20.0% | Q2 2025 net loss, cash of $5.1M plus ATM funds and trial timelines. |
| May 09 | Q1 2025 results | Neutral | +0.5% | Q1 2025 net loss, higher R&D, no revenue, and projected development milestones. |
| Mar 21 | Year-end 2024 results | Neutral | +0.4% | Reported 2024 net loss, $7.8M cash, increased R&D and HyBryte trial plans. |
Earnings and results updates have historically produced modestly positive one-day moves, with an average change of about 6.85%, despite ongoing net losses and funding needs.
Over the past year, Soligenix’s earnings and results releases have consistently highlighted net losses, limited or no revenue, and a focus on cash runway, alongside progress across HyBryte™, SGX945, and SGX302. Cash balances ranged around the mid‑single‑digit million level, with guidance on runway extending through 2025 and into 2026. These updates often paired financial detail with clinical and regulatory milestones, and prior earnings‑tagged announcements around 2024–2025 were followed by generally positive single‑day share reactions.
Historical Comparison
Past earnings and results releases for SNGX saw average one‑day moves of about 6.85%, generally positive. Today’s -6.89% move is similar in size but opposite in direction.
Earnings updates have tracked a progression from funding HyBryte™ Phase 3 development and Phase 2 programs in SGX945 and SGX302 toward later‑stage milestones, while repeatedly emphasizing cash balances, runway, and ongoing net losses.
Market Pulse Summary
This announcement combines Q1 2026 financials with strategic updates following the FLASH2 Phase 3 futility outcome. Soligenix reported a net loss of $2.8 million, no revenue, and cash of about $6.0 million, alongside an indicated runway into the second quarter of 2027. The company highlighted potential advancement of SGX945 in Behçet’s Disease and prior positive Phase 2a data for SGX302 in psoriasis. Investors may track future updates on strategic alternatives, regulatory interactions, and development plans for these programs.
Key Terms
cutaneous T-cell lymphoma medical
orphan drug designation regulatory
Promising Innovative Medicine (PIM) designation regulatory
Data Monitoring Committee technical
AI-generated analysis. Not financial advice.
"We remain disappointed with the unanticipated outcome of the FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "Despite the fact that HyBryte™ (synthetic hypericin) demonstrated statistically significant reductions in cutaneous T-cell lymphoma (CTCL) lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study. Over the coming weeks, we will analyze the data to better determine why the study did not meet expectations. If there is any clarity gained from further analysis of the dataset, especially with respect to specific subsets of patients that may benefit from HyBryte™ therapy, then we intend to communicate our findings and explore follow-up discussions with the European Medicines Agency (EMA) and the Food and Drug Administration (FDA)."
With approximately
Soligenix Recent Updates
- On April 28, 2026, the Company announced that the Data Monitoring Committee completed the interim efficacy analysis of its pivotal Phase 3 FLASH2 trial evaluating HyBryte™ in the treatment of CTCL and recommended the study halt for futility. To view this press release, please click here.
- On April 2, 2026, the Company announced that the positive results of its comparability study evaluating HyBryte™ versus Valchlor® (mechlorethamine) for the treatment of CTCL have been published in Oncology and Therapy. To view this press release, please click here.
Financial Results – Quarter Ended March 30, 2026
Soligenix had no revenue or related costs for the quarter ended March 31, 2026 and 2025, respectively.
Soligenix's net loss was
Research and development expenses were
General and administrative expenses were
As of March 31, 2026, the Company's cash position was approximately
About Soligenix, Inc.
Soligenix is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing synthetic hypericin for the treatment of psoriasis (SGX302), and our first-in-class Innate Defense Regulator (IDR) technology, dusquetide, for the treatment of inflammatory diseases, including aphthous ulcers in Behçet's Disease (BD) (SGX945) and oral mucositis in head and neck cancer (SGX942). We were developing HyBryte™ (SGX301 or synthetic hypericin sodium), a photodynamic therapy utilizing visible light, for the treatment of cutaneous T-cell lymphoma (CTCL) in a Phase 3 study called "FLASH2" (Fluorescent Light Activated Synthetic Hypericin 2). The Data Monitoring Committee completed its interim efficacy analysis of the FLASH2 trial during April 2026, and under the terms of the interim analysis, the study was recommended to halt for futility. We are in the process of analyzing the data to better determine why the study did not meet expectations.
Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and X at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected timing and results of clinical trials and the expected timing of regulatory submissions and approvals. In light of the discontinuation of the FLASH2 study, the Company's ability to continue as a going concern will be dependent upon its ability to develop and commercialize its remaining pipeline assets, including dusquetide for the treatment of Behçet's Disease, to identify and acquire or in-license additional product candidates or technologies, and to raise sufficient capital to fund such development and any such acquisitions. There can be no assurance that the Company will be able to obtain financing on acceptable terms, if at all, that suitable acquisition or in-licensing opportunities will be available, or that any of its remaining or future development programs will be successful. If the Company is unable to raise sufficient capital or otherwise advance its remaining assets, it may be required to significantly curtail or cease its operations, sell or otherwise dispose of its assets, or pursue dissolution and liquidation. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results-302766364.html
SOURCE SOLIGENIX, INC.